Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer

被引：0
|
作者：
Craig A. Vargo
Michael J. Berger
Gary Phillips
Ewa Mrozek
机构：
[1] The Ohio State University Wexner Medical Center,Department of Pharmacy, The James Cancer Hospital and Solove Research Institute
[2] The Ohio State University,Center for Biostatistics
[3] The Ohio State University Wexner Medical Center,Division of Medical Oncology, Department of Internal Medicine
来源：
Supportive Care in Cancer | 2016年 / 24卷
关键词：
Everolimus; Adverse events; Breast cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2913 / 2918
页数：5
相关论文
共 50 条
  • [41] Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer
    Blok, Erik J.
    Kroep, Judith R.
    Kranenbarg, Elma Meershoek-Klein
    Duijm-de Carpentier, Marjolijn
    Putter, Hein
    Liefers, Gerrit-Jan
    Nortier, Johan W. R.
    Rutgers, Emiel J. Th.
    Seynaeve, Caroline M.
    van de Velde, Cornelis J. H.
    EUROPEAN JOURNAL OF CANCER, 2018, 95 : 59 - 67
  • [42] Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
    Fakih, M.
    Vincent, M.
    CURRENT ONCOLOGY, 2010, 17 : S18 - S30
  • [43] Occurrence of neutropenia in women with breast cancer during chemotherapy treatment
    Gozzo, Thais de Oliveira
    do Nascimento, Talita Garcia
    Panobianco, Marislei Sanches
    de Almeida, Ana Maria
    ACTA PAULISTA DE ENFERMAGEM, 2011, 24 (06) : 810 - 814
  • [44] Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
    Labadie, Brian W.
    Morris, David S.
    Bryce, Alan H.
    Given, Robert
    Zhang, Jingsong
    Abida, Wassim
    Chowdhury, Simon
    Patnaik, Akash
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 673 - 686
  • [45] Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
    Xi, Jing
    Oza, Aabha
    Thomas, Shana
    Ademuyiwa, Foluso
    Weilbaecher, Katherine
    Suresh, Rama
    Bose, Ron
    Cherian, Mathew
    Hernandez-Aya, Leonel
    Frith, Ashley
    Peterson, Lindsay
    Luo, Jingqin
    Krishnamurthy, Jairam
    Ma, Cynthia X.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (02): : 141 - 147
  • [46] Secondary malignancies developing during metastatic breast cancer treatment
    Nikolic, N. M.
    Tomasevic, Z.
    Jelic, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] Receptor status heterogeneity during metastatic breast cancer treatment
    Geurts, S.
    Hermans, K.
    Van den Berkmortel, F.
    Tol, J.
    Heijns, J. B.
    Dercksen, M.
    Vriens, B. E. P. J.
    Aaldering, K.
    Pepels, M.
    Peters, N.
    van de Winkel, L.
    Boon, E.
    Teeuwen, N.
    van Kats, M.
    Tjan-Heijnen, V.
    ANNALS OF ONCOLOGY, 2024, 35 : S385 - S385
  • [48] Octreotide as first-line treatment for women with metastatic breast cancer
    Ingle, JN
    Kardinal, CG
    Suman, VJ
    Krook, JE
    Hatfield, AK
    INVESTIGATIONAL NEW DRUGS, 1996, 14 (02) : 235 - 237
  • [49] The place of conventional anthracyclins in first line metastatic breast cancer treatment
    Bonneterre, J.
    ONCOLOGIE, 2007, 9 : S9 - S11
  • [50] First-line treatment with epirubicin and vinorelbine in metastatic breast cancer
    Vici, P
    Colucci, G
    Gebbia, V
    Amodio, A
    Giotta, F
    Belli, F
    Conti, F
    Gebbia, N
    Pezzella, G
    Valerio, MR
    Brandi, M
    Pisconti, S
    Durini, E
    Giannarelli, D
    Lopez, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2689 - 2694
12345